No abstract available.
Mongolian Spot* ; Nevus, Blue*

No abstract available.
Adenocarcinoma*

Tinea incognito is a dermatophytic infection induced by immunosuppressive agents that lacks the classic features of a typical fungal infection. Although the treatment of tinea incognito is simple and relatively easy, its clinical manifestation varies and can masquerade as various skin disorders, causing misdiagnosis and thus preventing prompt and appropriate treatment. Here, we report an interesting case of tinea incognito occurring after topical steroid administration in an immunosuppressed patient with dermatitis artefacta. A 40-year-old female patient who had been taking systemic glucocorticoid for 4 years for chronic inflammatory demyelinating polyneuropathy presented with itching multiple erythematous erosive lesions on the face and upper chest for 2 months. Initial biopsy produced nonspecific findings. The skin lesion was aggravated and became polycyclic and erythematous; after azathioprine was added, her chronic inflammatory demyelinating polyneuropathy became aggravated. A second biopsy confirmed hyphae in the cornified layer. Complete remission was achieved after admonishing oral terbinafine and topical amorolfine.
Adult ; Azathioprine ; Biopsy ; Dermatitis ; Diagnostic Errors ; Female ; Humans ; Hyphae ; Immunosuppressive Agents ; Polyneuropathies ; Pruritus ; Skin ; Thorax ; Tinea*

BACKGROUND: Tacrolimus ointment is a topical immunomodulator. Preliminary studies suggest that 0.1% tacrolimus is effective and has a proactive effect on atopic dermatitis with fewer complications than topical corticosteroids. OBJECTIVE: The purpose of this study was to evaluate the efficacy and safety of tapering treatment with 0.1% tacrolimus ointment and its impact on quality of life in adult patients with atopic dermatitis in Korea. Korean adults with atopic dermatitis. METHODS: A total of 53 patients aged 15 to 54 years with moderate to severe atopic dermatitis applied 0.1% tacrolimus ointment for 12 weeks. The 0.1% tacrolimus ointment was applied along with a topical corticosteroid once daily during the 2-week induction phase and twice daily during the 2-week transitional phase. During the 8-week maintenance phase, the corticosteroid was discontinued and the 0.1% tacrolimus ointment alone was applied twice daily for 2 weeks and twice weekly for 6 weeks. Efficacy and quality of life were evaluated by the SCORAD and the Dermatology Life Quality Index (DLQI), respectively. RESULTS: SCORAD and DLQI values were significantly improved after 12 weeks of treatment. Symptoms were markedly improved after 2 weeks of applying the 0.1% tacrolimus ointment and the improvements were well maintained after tapering. Continuous improvement was observed throughout the study. Transient skin burning and itching occurred in about 43% of the patients, but gradually decreased in about 30% after continuous application. CONCLUSION: Tapering treatment with 0.1% tacrolimus ointment is safe and effective, and may replace the long-term use of topical corticosteroids, avoiding corticosteroid-associated adverse effects while maintaining clinical control and improving the quality of life of adult atopic dermatitis patients.
Adrenal Cortex Hormones ; Adult* ; Burns ; Dermatitis, Atopic* ; Dermatology ; Humans ; Korea ; Pruritus ; Quality of Life ; Skin ; Tacrolimus* ; Treatment Outcome

No abstract available.
Adult* ; Humans ; Myofibroma* ; Thigh*

No abstract available.
Adult* ; Humans ; Myofibroma* ; Thigh*

No abstract available.
Skin Diseases* ; Skin*

No abstract available.
Skin Diseases* ; Skin*

No abstract available.
Breast* ; Lichen Sclerosus et Atrophicus* ; Lichens* ; Vitiligo* ; Vulva*

Objectives: This study was conducted to systematically summarize trends in research concerning patients with coronavirus disease 2019 (COVID-19) as reported in Korean medical journals. Methods: We performed a literature search of KoreaMed from January 2020 to September 2022. We included only primary studies of patients with COVID-19. Two reviewers screened titles and abstracts, then performed full-text screening, both independently and in duplicate. We first identified the 5 journals with the greatest numbers of eligible publications, then extracted data pertaining to the general characteristics, study population attributes, and research features of papers published in these journals. Results: Our analysis encompassed 142 primary studies. Of these, approximately 41.0% reported a funding source, while 3.5% disclosed a conflict of interest. In 2020, 42.9% of studies included fewer than 10 participants; however, by 2022, the proportion of studies with over 200 participants had increased to 40.6%. The most common design was the cohort study (48.6%), followed by case reports/series (35.2%). Only 3 randomized controlled trials were identified. Studies most frequently focused on prognosis (58.5%), followed by therapy/intervention (20.4%). Regarding the type of intervention/exposure, therapeutic clinical interventions comprised 26.1%, while studies of morbidity accounted for 13.4%. As for the outcomes measured, 50.7% of studies assessed symptoms/clinical status/improvement, and 14.1% evaluated mortality. Conclusions Employing a systematic approach, we examined the characteristics of research involving patients with COVID-19 that was published in Korean medical journals from 2020 onward. Subsequent research should assess not only publication trends over a longer timeframe but also the quality of evidence provided.